1. Indications and Usage
\nHepatocellular Carcinoma (HCC): Treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy .
\nDifferentiated Thyroid Cancer (DTC): Treatment of patients with progressive, locally advanced, metastatic, or radioactive iodine-refractory differentiated thyroid cancer .
\nRenal Cell Carcinoma (RCC): In combination with everolimus for patients with advanced RCC who have received prior anti-angiogenic therapy .
\n2. Dosage and Administration
\nAdministration: Oral administration. Swallow capsules whole. If swallowing is difficult, the capsule contents may be dispersed in water or apple juice (do not crush), let stand for 10 minutes, stir for 3 minutes, and drink immediately. Rinse with more liquid and drink .
\nFood Requirement: Can be taken with or without food .
\nStandard Dose:
\nHCC: 12 mg once daily (if body weight \u226560 kg) or 8 mg once daily (if body weight <60 kg) .
\nDTC: 24 mg once daily .
\nMissed Dose: If a dose is missed and can be taken at least 12 hours before the next scheduled dose, take it as soon as possible. Otherwise, skip the missed dose .
\n3. Mechanism of Action
\nLenvatinib is a multi-kinase inhibitor. It inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3, which are critical for angiogenesis.
\nIt also inhibits other receptor tyrosine kinases (RTKs) involved in tumor angiogenesis and oncogenic signaling, including fibroblast growth factor receptors (FGFRs), PDGFR\u03b1, KIT, and RET .
\n4. Safety and Warnings
\nHypertension: Severe hypertension is common. Blood pressure must be monitored and controlled before and during treatment .
\nProteinuria and Nephrotic Syndrome: Monitor urine protein regularly. Severe proteinuria or nephrotic syndrome requires dose interruption or discontinuation .
\nCardiac Dysfunction: Can cause heart failure. Monitor for signs of heart failure .
\nHepatotoxicity: Monitor liver function tests regularly .
\nGastrointestinal Perforation and Fistula: Fatal or serious cases have occurred. Permanently discontinue if perforation occurs .
\nThyroid Dysfunction: Monitor thyroid function, especially in patients with DTC .
\nEmbryo-Fetal Toxicity: May cause fetal harm. Contraception is required for females and males during treatment and for at least 1 week after the final dose .
\n5. Adverse Reactions
\nCommon adverse reactions (incidence \u226530%) include:
\nHypertension, Fatigue, Diarrhea.
\nArthralgia, Myalgia, Decreased appetite.
\nNausea, Vomiting, Stomatitis, Headache.
\nWeight decreased, Proteinuria, Palmar-plantar erythrodysesthesia syndrome (PPES), Dysphonia .
\n6. Drug Interactions
\nCYP3A Substrate: Lenvatinib is metabolized by CYP3A4. Avoid co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) as they may alter drug exposure .
\nP-gp Substrate: Lenvatinib is a P-gp substrate. P-gp inhibitors may increase its exposure .
\n7. Pharmaceutical Information
\nChemical Name: 4-[3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy]-7-methanesulfonate<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u4e50\u536b\u739b\u00ae (Lenvima\u00ae)
\nGeneric Name: Lenvatinib Mesilate
\nStrength: 4 mg per capsule, 30 capsules per box
\nManufacturer: Patheon Inc.
\nMarketing Authorization Holder: Eisai Europe Ltd.\uff1b\u56fd\u5185\u8054\u7cfb\u5355\u4f4d\uff1a\u536b\u6750\uff08\u4e2d\u56fd\uff09\u836f\u4e1a\u6709\u9650\u516c\u53f8
\nApproval Date in China: September 4, 2018
\nRegistration Number: \u56fd\u836f\u51c6\u5b57H20180052
\nStorage: Store below 30\u00b0C, sealed and protected from light, keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Lenvatinib Mesilate\uff08Lenvima\uff09<\/p>\n","protected":false},"featured_media":2867,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[92],"product_cat":[26],"product_tag":[],"class_list":["post-2865","product","type-product","status-publish","has-post-thumbnail","product_brand-eisai","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n